PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9292569-5	1997	Afterward, we studied the effects of enalapril administered for 4 weeks on vWF levels and proteinuria in a group of 11 IgAN patients with normal renal function and proteinuria > or = 1 g/d.	Enalapril	37-46	von Willebrand factor	Homo sapiens	75-78	
9292569-6	1997	After 2 weeks on enalapril treatment, both vWF levels and proteinuria had significantly decreased (vWF: 158% +/- 122% to 117% +/- 72%, P < 0.05; proteinuria: 1.6 +/- 0.7 g/d to 0.9 +/- 0.4 g/ d, P < 0.05).	Enalapril	17-26	von Willebrand factor	Homo sapiens	43-46	
9292569-6	1997	After 2 weeks on enalapril treatment, both vWF levels and proteinuria had significantly decreased (vWF: 158% +/- 122% to 117% +/- 72%, P < 0.05; proteinuria: 1.6 +/- 0.7 g/d to 0.9 +/- 0.4 g/ d, P < 0.05).	Enalapril	17-26	von Willebrand factor	Homo sapiens	99-102	
9292569-7	1997	After enalapril withdrawal, both vWF and proteinuria significantly increased.	Enalapril	6-15	von Willebrand factor	Homo sapiens	33-36	
12398965-9	2002	Enalapril treatment, but not placebo, reduced plasma von Willebrand factor (p = 0.03) and ADMA levels (p = 0.01) and increased NOx levels (p = 0.01) and the ratio of L-arginine to ADMA (p <0.01).	Enalapril	0-9	von Willebrand factor	Homo sapiens	53-74